Advanced

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

Choi, M. Y.; Clarke, A. E.; St Pierre, Y.; Hanly, J. G.; Urowitz, M. B.; Romero-Diaz, J.; Gordon, C.; Bae, S. C.; Bernatsky, S. and Wallace, D. J., et al. (2017) In Lupus 26(10). p.1051-1059
Abstract

Autoantibodies to dense fine speckles 70 (DFS70) are purported to rule out the diagnosis of SLE when they occur in the absence of other SLE-related autoantibodies. This study is the first to report the prevalence of anti-DFS70 in an early, multinational inception SLE cohort and examine demographic, clinical, and autoantibody associations. Patients were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis. The association between anti-DFS70 and multiple parameters in 1137 patients was assessed using univariate and multivariate logistic regression. The frequency of anti-DFS70 was 7.1% (95% CI: 5.7-8.8%), while only 1.1% (95% CI: 0.6-1.9%) were monospecific for... (More)

Autoantibodies to dense fine speckles 70 (DFS70) are purported to rule out the diagnosis of SLE when they occur in the absence of other SLE-related autoantibodies. This study is the first to report the prevalence of anti-DFS70 in an early, multinational inception SLE cohort and examine demographic, clinical, and autoantibody associations. Patients were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis. The association between anti-DFS70 and multiple parameters in 1137 patients was assessed using univariate and multivariate logistic regression. The frequency of anti-DFS70 was 7.1% (95% CI: 5.7-8.8%), while only 1.1% (95% CI: 0.6-1.9%) were monospecific for anti-DFS70. In multivariate analysis, patients with musculoskeletal activity (Odds Ratio (OR) 1.24 [95% CI: 1.10, 1.41]) or with anti-β2 glycoprotein 1 (OR 2.17 [95% CI: 1.22, 3.87]) were more likely and patients with anti-dsDNA (OR 0.53 [95% CI: 0.31, 0.92]) or anti-SSB/La (OR 0.25 [95% CI: 0.08, 0.81]) were less likely to have anti-DFS70. In this study, the prevalence of anti-DFS70 was higher than the range previously published for adult SLE (7.1 versus 0-2.8%) and was associated with musculoskeletal activity and anti-β2 glycoprotein 1 autoantibodies. However, 'monospecific' anti-DFS70 autoantibodies were rare (1.1%) and therefore may be helpful to discriminate between ANA-positive healthy individuals and SLE.

(Less)
Please use this url to cite or link to this publication:
@article{be2f921d-da03-4563-b0ed-242edb3c7dc6,
  abstract     = {<p>Autoantibodies to dense fine speckles 70 (DFS70) are purported to rule out the diagnosis of SLE when they occur in the absence of other SLE-related autoantibodies. This study is the first to report the prevalence of anti-DFS70 in an early, multinational inception SLE cohort and examine demographic, clinical, and autoantibody associations. Patients were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis. The association between anti-DFS70 and multiple parameters in 1137 patients was assessed using univariate and multivariate logistic regression. The frequency of anti-DFS70 was 7.1% (95% CI: 5.7-8.8%), while only 1.1% (95% CI: 0.6-1.9%) were monospecific for anti-DFS70. In multivariate analysis, patients with musculoskeletal activity (Odds Ratio (OR) 1.24 [95% CI: 1.10, 1.41]) or with anti-β2 glycoprotein 1 (OR 2.17 [95% CI: 1.22, 3.87]) were more likely and patients with anti-dsDNA (OR 0.53 [95% CI: 0.31, 0.92]) or anti-SSB/La (OR 0.25 [95% CI: 0.08, 0.81]) were less likely to have anti-DFS70. In this study, the prevalence of anti-DFS70 was higher than the range previously published for adult SLE (7.1 versus 0-2.8%) and was associated with musculoskeletal activity and anti-β2 glycoprotein 1 autoantibodies. However, 'monospecific' anti-DFS70 autoantibodies were rare (1.1%) and therefore may be helpful to discriminate between ANA-positive healthy individuals and SLE.</p>},
  author       = {Choi, M. Y. and Clarke, A. E. and St Pierre, Y. and Hanly, J. G. and Urowitz, M. B. and Romero-Diaz, J. and Gordon, C. and Bae, S. C. and Bernatsky, S. and Wallace, D. J. and Merrill, J. T. and Isenberg, D. A. and Rahman, A. and Ginzler, E. M. and Petri, M. and Bruce, I. N. and Dooley, M. A. and Fortin, P. and Gladman, D. D. and Sanchez-Guerrero, J. and Steinsson, K. and Ramsey-Goldman, R. and Khamashta, M. A. and Aranow, C. and Alarcón, G. S. and Manzi, S. and Nived, O. and Zoma, A. A. and Van Vollenhoven, R. F. and Ramos-Casals, M. and Ruiz-Irastorza, G. and Lim, S. S. and Kalunian, K. C. and Inanc, M. and Kamen, D. L. and Peschken, C. A. and Jacobsen, S. and Askanase, A. and Buyon, J. and Mahler, M. and Fritzler, Marvin J.},
  issn         = {0961-2033},
  keyword      = {Antinuclear antibodies,autoantibodies,DFS70,SLE},
  language     = {eng},
  month        = {09},
  number       = {10},
  pages        = {1051--1059},
  publisher    = {SAGE Publications Ltd},
  series       = {Lupus},
  title        = {The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients},
  url          = {http://dx.doi.org/10.1177/0961203317692437},
  volume       = {26},
  year         = {2017},
}